Vasculitis as an adverse event following immunization – Systematic literature review
Caterina Bonetto(Italian Medicines Agency), Jan Bonhoeffer(University Children’s Hospital Basel), Saša Živković(University of Pittsburgh), Barbara Pahud(Children's Mercy Hospital), Novilia Sjafri Bachtiar(PT Bio Farma (Indonesia)), Merita Kucuku(University of Medicine Tirana), Giovanna Zanoni(Azienda Ospedaliera Universitaria Integrata Verona), Carmela Santuccio(Italian Medicines Agency), Robert D. M. Hadden(Erasmus MC), Francesco Trotta(Italian Medicines Agency), Frederick Varricchio(Rutgers, The State University of New Jersey), Yolanda Brauchli Pernus, Seza Özen(Hacettepe University), Rebecca E. Chandler(Uppsala Monitoring Centre), Graciela S. Alarcón(University of Alabama at Birmingham), Karina A. Top(Dalhousie University), Robert P. Wise(Center for Biologics Evaluation and Research), Patrizia Felicetti(Italian Medicines Agency), Giampiero Girolomoni(University of Verona)
Cited by 110
Related Papers
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
|New England Journal of Medicine|2001|3.7k
EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides
|Annals of the Rheumatic Diseases|2005|838
EULAR recommendations for the management of familial Mediterranean fever
|Annals of the Rheumatic Diseases|2016|593
Regulatory Activity of Autocrine IL-10 on Dendritic Cell Functions
|The Journal of Immunology|2001|553
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept
|Arthritis & Rheumatism|2002|448